Scientists have shown that a new treatment can slow down the immune attack that causes Type 1 diabetes, delaying the point at which someone is diagnosed with the condition. 

We’re delighted to announce our continued commitment to revolutionise the treatment of Type 1 diabetes, by awarding £490,000 – in partnership with JDRF – to fund the next generation of immunotherapy research.